A Phase 1 Study of Cyclophosphamide and Alemtuzumab in CD52 Positive Relapsed/Refractory Double-Hit Lymphoma, Diffuse Large B-cell Lymphoma or High Grade B-cell Lymphoma, NOS With MYC and BCL-2 Over-expression, MYC-Positive Transformed Follicular Lymphoma, and CD52 Positive Mature T-cell Lymphoproliferative Disorder

Trial Profile

A Phase 1 Study of Cyclophosphamide and Alemtuzumab in CD52 Positive Relapsed/Refractory Double-Hit Lymphoma, Diffuse Large B-cell Lymphoma or High Grade B-cell Lymphoma, NOS With MYC and BCL-2 Over-expression, MYC-Positive Transformed Follicular Lymphoma, and CD52 Positive Mature T-cell Lymphoproliferative Disorder

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Lymphoproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 30 Jul 2017.
    • 28 Jun 2017 Planned initiation date changed from 30 May 2017 to 30 Jun 2017.
    • 03 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top